Case Study Reports:

[1] Nixon et al, Benefit Risk Wave 1 Case study report Natalizumab, May 2013
[2] Nixon et al, Benefit Risk Wave 2 Case study report Natalizumab, March 2013
[3] Nixon et al, A case study using the PrOACT-URL and BRAT frameworks for structured benefit risk assessment. Biom. J. doi: 10.1002/bimj.201300248 (2015)
[4] Waddingham et al, A Bayesian approach to probabilistic sensitivity analysis in structured benefit-risk assessment. Waddingham et al - Biom. J.. doi: 10.1002/bimj.201300254 (2015)